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Abstract 
Ready access to health research studies is becoming more important as 
researchers, and their funders, seek to maximise the opportunities for scientific 
innovation and health improvements. Large-scale population-based prospective 
studies are particularly useful for multidisciplinary research into the causes, 
treatment and prevention of many different diseases. UK Biobank has been 
established as an open-access resource for public health research, with the intention 
of making the data as widely available as possible in an equitable and transparent 
manner. Access to UK Biobank’s unique breadth of phenotypic and genetic data has 
attracted researchers worldwide from across academia and industry. As a 
consequence, it has enabled scientists to perform world-leading collaborative 
research. Moreover, open access to an already deeply characterized cohort has 
encouraged both public and private sector investment in further enhancements to 
make UK Biobank an unparalleled resource for public health research and an 
exemplar for the development of open access approaches for other studies. 
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Introduction 
Over the last few decades, several large-scale observational studies have been 
established to enable epidemiological research into the causes of the major diseases 
of middle and old age. Many of these studies express a commitment to open data 
sharing in order to facilitate research efforts, whilst ensuring appropriate commitment 
to participant confidentiality, consent and data protection regulations. This has 
become even more important in the era of genomics where meta-analyses of data 
from multiple (largely retrospective) studies are essential to achieve the numbers 
required to perform population-based genetic research [1, 2] and often requires 
collaboration with the team that set up the study. However, few epidemiological 
studies have been designed from the outset to be an open-access resource 
available to academic and commercial researchers alike from around the world, with 
no preferential access.  
This article describes the access policy of UK Biobank, how it has developed over 
time in relation to both the use of data and biological samples, and how it has 
facilitated collaborative research whereby the results can be shared by all.  
 
UK Biobank 
UK Biobank is a large, prospective cohort study of 500,000 participants aged 40 to 
69 years at the time of their baseline assessment visit during 2006-2010. The study 
was established to enable research into the lifestyle, environmental and genomic 
determinants of life-threatening and disabling diseases of middle and old age.  A 
vast amount of data was collected at recruitment, including self-reported lifestyle and 
medical information (supplemented subsequently by antecedent information from 
health records), a wide range of physical measures (e.g. blood pressure, 
anthropometry, spirometry) and biological samples (blood, urine and saliva), of which 
further details are provided elsewhere [3]. All of the data can be viewed on UK 
Biobank’s online Data Showcase, including summary statistics for each data-field 
available for research [4].  
Since recruitment, UK Biobank has continued to be enhanced by converting the 
information contained in the biological samples, which are limited and depletable, 
into data that can be widely shared. This has included cohort-wide genotyping (with 
subsequent imputation to over 90 million variants) [5] and whole exome sequencing, 
making it one of the largest studies in the world with detailed data on genetics, 
lifestyle and health outcomes. A range of blood and urine biomarkers of interest for 
research into common conditions (such as cardiovascular disease, cancer and 
diabetes) are also available for all 500,000 participants [6]. UK Biobank continues to 
collect extensive data directly from participants. This includes a series of web-based 
questionnaires sent to all participants with an email address (n=330,000) about 
particular exposures (e.g. diet, occupation) and conditions (e.g. cognition, mental 
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health, pain), objective physical activity monitoring (100,000), and ongoing 
assessments of multi-modal imaging (target of 100,000) and cardiac monitoring 
(target of >20,000).  
As UK Biobank is a prospective study, considerable efforts are spent in following the 
health of all participants through linkage to electronic health datasets, including 
death and cancer registries, and primary and secondary care records (Fig. 1). 
Several thousand incident cases of the most common conditions have already been 
identified, with many more cases expected to accrue over the next few years (Table 
1). Efforts are underway to generate algorithmically-derived health outcomes in order 
to facilitate a wide range of research using standardised outcome variables [7].  
 
Access to the resource 
UK Biobank was set up on the basis of a clear intention from its two core funders 
(the Medical Research Council and Wellcome Trust) as a de-facto open-access 
resource, with the aim to make the data as widely available as possible, with an 
equitable and transparent access policy [8].  
In order to apply for access to data from UK Biobank, each applicant must 
demonstrate that they are a bona fide researcher (i.e. they must register from, and 
be affiliated with, an approved research institute) and the application must involve 
health-related research that is in the public interest. All applicants are treated the 
same – whether academic, governmental, charitable or commercial, or whether from 
domestic or international organisations – and all applications are assessed according 
to the same consistent criteria.  
All access applications are discussed and approved by the Access Sub-Committee 
(ASC) of the UK Biobank Board. Access to data is relatively permissive, and review 
by the ASC seeks only to ensure that the research is viable and meets the 
requirements. The ASC’s main responsibility is making strategic access decisions, 
particularly regarding contentious matters and the use of biological samples. Ethics 
advice is provided to the ASC on an independent consultancy basis by Oxford 
University’s Ethox group [9].  
Lay summaries of each approved application are published on the website. A 
standard material transfer agreement (MTA) is signed prior to any data delivery, and 
governs how a researcher can use the data. All researchers must publish (or 
otherwise make publicly available) the findings of their research and return any 
derived data-fields, and the methods used to generate them, back to UK Biobank. 
These data are available to other registered researchers, thereby encouraging 
transparency and reproducibility in scientific methods.  
UK Biobank is established as a charity with access charges (reviewed on a periodic 
basis) which are set at a level that covers the costs of managing the access 
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application process. In order to encourage use by potentially disadvantaged 
researchers, fees are subsidised for research groups from low and low-to-middle-
income countries (assessed according to the current World Bank guidelines) and for 
student projects.  
Evolution of UK Biobank’s access approach 
When the UK Biobank resource opened to researchers in April 2012, a relatively 
cautious approach to data access was taken. At that time, the application process 
consisted of two phases, a preliminary form (for early identification of projects not 
deemed compliant with UK Biobank’s purposes) and a main form, each requiring 
separate payment and approval at various levels. This involved reviews from the 
scientific team to ensure the project was well-defined and health-related, the data 
analysts to ensure the selected data-fields were appropriate, UK Biobank’s Principal 
Investigator (UKBPI) to make a final check, and the ASC to provide official 
assessment with approval or rejection (with a right of appeal).  
Initially, researchers had to have a clear, well-defined research question with a focus 
on specific exposures and outcomes and justify their requests for data-fields. 
Datasets were restricted to only those data and participants that the researcher 
required (e.g., women only or specific case-control subsets). As the sheer size and 
depth of available data has increased, particularly following inclusion of the genotype 
data into the resource, the requirements have been relaxed to enable research that 
is broader in scope and often exploratory in nature (i.e. hypothesis-generating), with 
about one-third of research groups requesting the entire core dataset. As interest in 
the resource has grown over time (see Figs. 2.a and 2.b), UK Biobank further 
streamlined its approach when it launched a new access management system in 
February 2018 [10]. Interested researchers still have to register with UK Biobank in 
order to verify their research credentials, but the application comprises a single 
simplified form with easier selection of data-fields. In a further revision of the 
process, UK Biobank intends to provide the entire core dataset (excluding potentially 
identifying and particularly complex and/or large data) for each research project. It is 
anticipated this will substantially streamline the process further as it removes the 
requirement both for researchers to select each data-field and for UK Biobank to 
produce bespoke datasets.  
Most data-only applications are fundamentally non-contentious (with 99% approved), 
so further streamlining efforts have led to delegation of approval to the scientific 
team, with the ability to escalate applications to the UKBPI and ASC if considered 
necessary. These changes have led to a shorter turnaround time for applications: the 
time from application submission to data release has reduced from 69 weeks in 2013 
to 24 weeks by the end of 2018. It is intended that this will continue to be reduced 
following the provision of a default core dataset and the removal of an upfront 
payment stage, to be implemented in mid-2019.    
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Access to biological samples  
Applications that request access to biological samples undergo much more stringent 
consideration, as the samples are a limited and depletable resource. The science 
behind the request is reviewed rigorously and external expert advice sought, where 
necessary [11]. When the resource was established, it was envisaged that access to 
the biological samples (blood, urine and saliva) for assays would be co-ordinated 
around case-control subsets “nested” within the whole cohort, as performed in 
virtually all previous prospective studies to date. However, it became apparent that 
this would not be the most efficient (or cost-effective) way of developing the resource 
for researchers to study the causes of many different health outcomes. This is 
because assays of samples in nested case-control comparisons based on different 
subsets of the participants preclude reliable comparisons across the full cohort. In 
contrast, generating assay data from biological samples for the entire cohort at one 
time facilitates good quality control by reducing measurement error and assay drift. 
This strategy also minimises sample depletion and is highly cost-effective since, in 
the long-term, the costs of conducting assays at one time for all of the participants 
are likely to be less than the costs of multiple retrievals. As such, requests for UK 
Biobank samples (which comprise 4% of all submitted applications; Fig. 2.c) are now 
only considered where they are undertaken on the whole (or a large subset) of the 
cohort, the assay data are applicable to a range of researchers, the assay method is 
well validated and uses minimal sample volume, and the laboratory can adhere to 
strict quality control measures [11].  
 
Access to participants for third party studies 
At recruitment to the study, participants consented to being re-contacted by UK 
Biobank. This includes communications to inform participants about the progress of 
the study (e.g., via an annual newsletter), and invitations to join third-party studies. 
As with samples, UK Biobank considers that re-contact of participants to be a 
depletable resource and is mindful not to over-burden participants with such 
invitations. Any application to use UK Biobank as a recruitment pool for third party 
studies (which comprise ~1% of all submitted applications; Fig. 2.c) is carefully 
reviewed by the ASC to ensure that there is sufficient scientific justification for such 
re-contact. As UK Biobank participants consented on the understanding that no 
results would be fed back to them following their assessment visits, care is taken to 
ensure that re-contact does not represent implicit feedback of information of which 
participants are not aware. As such, recruitment based on genotype or on phenotype 
that is not explicitly self-reported by the participant is highly restricted [12]. 
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Who is using the data? 
Since 2012, over 10,000 researchers have registered to use the resource, over 
1,500 applications have been submitted and 1,000 projects are underway. The 
number of international researchers has steadily increased over time and now 
accounts for about three-quarters of all registrations and about two-thirds of all 
applications (Fig. 2.a and 2.b). Over 700 institutes worldwide have published using 
UK Biobank data. An independent analysis commissioned in 2018 highlighted that 
many non-UK institutes were using the resource with several major international 
groups – such as the Broad Institute/Harvard (USA), the University of Queensland 
(Australia), Erasmus University Medical Centre (Netherlands) and the Karolinska 
Institute (Sweden) – being particularly prolific users. True to the multidisciplinary 
nature of research, many research groups are collaborating with each other; for 
example, researchers from the Broad Institute/Harvard and the Universities of 
Oxford, Cambridge and Edinburgh frequently publish together, as do the Universities 
of Queensland and Edinburgh (Fig. 3.a). 
The majority (>95%) of applications are for data-only (Fig. 2.c); true to the 
prospective nature of the resource, nearly all applications request death and cancer 
data, approximately three-quarters request the genomic data, two-thirds the hospital-
inpatient data and one-third the imaging-derived phenotypes (i.e. variables 
generated from the raw imaging scans) (Fig. 2.d).  
 
Growing interest from industry 
The participant consent for UK Biobank is clear that access to the resource is 
available to commercial companies for use for health-related research on the same 
basis as academic researchers. Registered researchers from industry now account 
for 12% of all researchers as pharmaceutical and other commercial research groups 
realise the potential of the resource to accelerate drug discovery and develop 
machine-learning techniques for early detection of disease. Industry partners are 
also starting to enhance the resource further (for example, by supporting cohort-wide 
assays) in order to augment their own research aims, while at the same time 
benefiting the wider research community as the enhancements are shared with all 
researchers after a limited exclusivity period (now set at a fixed period of 9 months). 
The first major industry investment was by Regeneron Pharmaceuticals to perform 
whole exome sequencing of the whole cohort. The first 50,000 samples have been 
sequenced in partnership with GlaxoSmithKline and these data are now available to 
all researchers. The remaining 450,000 samples are being exome sequenced by 
Regeneron in partnership with Abbvie, Alnylam, AstraZeneca, Biogen, Pfizer, Bristol-
Myers Squibb and Takeda, and will be available to other researchers by the end of 
2020. In addition, whole genome sequencing (WGS) is also underway on 50,000 
participants, and it is anticipated that sequencing the remaining 450,000 participants 
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will be funded by a consortium of industry, government and charity funders, with data 
to become available to researchers over the next few years. In parallel, Nightingale 
Health, a biotech company from Finland, is measuring about 200 lipids and other 
circulating metabolites for all 500,000 participants. Government and charity funders 
have also provided funding for academic researchers to measure telomere length for 
all participants, and to collect data on heart arrhythmias via a dedicated heart 
monitor for 20,000 participants.   
In addition, academic and industry collaborations are underway to process the raw 
scans collected as part of the ongoing imaging assessment of 100,000 participants 
in order to generate imaging-derived variables that can be used more readily by the 
wider research community. Because of the unprecedented scale of the imaging sub-
study, this has necessitated the development of automated processing tools that can 
rapidly extract imaging-derived phenotypes. This includes phenotypes related to the 
structure and function of the brain (developed by The Wellcome Centre for 
Integrative Neuroimaging [13]), liver fat quantity and function (developed by 
Perspectum [14]), and detailed body composition measures (developed by  several 
groups, including Advanced MR Analytics AB in conjunction with Pfizer [15], and 
Klarismo). These imaging-derived phenotypes are now being widely used by the 
wider research community to characterise intermediate disease outcomes and to 
investigate biological mechanisms of disease.  
In this way, industry is effectively becoming a funder of UK Biobank, accelerating the 
rate at which the biological samples (e.g. through cohort-wide assays) and complex 
imaging data (e.g. raw magnetic resonance [MRI] scans) are converted into data that 
are potentially transformative in terms of the science they can support. Such large-
scale investment is not feasible from most public sector sources, underscoring the 
effectiveness of UK Biobank’s data sharing model.  
 
Research output 
The UK Biobank resource is generating an increasingly large and diverse research 
output related to identifying genetic and environmental risk factors for disease, with 
over 600 publications (Fig. 3.b) and over 10,000 citations (mostly in the last 2 years), 
as well as large numbers of conference abstracts, student projects, and 
methodological tools posted online.  
The availability of genomic data on such large numbers is transforming genetic 
research, with Genome-Wide Association Studies (GWAS) now considered routine. 
Indeed, research groups have already made summary GWAS statistics for 
thousands of phenotypic traits publicly available [16-18]. This, in turn, is accelerating 
research into using genetic variants to assess causality of associations (e.g. using 
Mendelian Randomization approaches [19-21]) or for risk stratification purposes (e.g. 
using polygenic risk scores [22-25]).  For the imaging research community, where 
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MRI data on this scale is unprecedented, both methodological and analytical 
advancements are underway to maximise the scientific utility of these data. For 
example, machine learning applications are being used to perform segmentation of 
MRI scans and to predict health outcomes [26].  
 
Linkage to health data is allowing prospective analyses to be undertaken [27-29] 
and, as the cohort continues to mature, longitudinal research into the causes of a 
wide range of health outcomes will be possible. To date, cardiovascular, metabolic 
disease and cancer are the most common outcomes of research interest (Fig 3.c). 
However, this may well change as the numbers of incident cases of rarer conditions 
accrue over time.  For example, 3,000 and 6,000 incident cases of osteoarthritis and 
hip fracture, respectively, will become available by 2022, enabling unprecedented 
research into their aetiology and progression (Table 1). In addition, the availability of 
primary care data in UK Biobank – which has hitherto not been available to UK 
cohort studies at a national level – will facilitate research into conditions (such as 
asthma, headaches, allergies, back pain, arthritis, diabetes, etc.) that are 
substantially under-ascertained when based only on hospital admission data. For 
example, the incorporation of primary care data in UK Biobank is anticipated to more 
than double the numbers of incident cases of chronic obstructive pulmonary disease 
(COPD) and dementia compared with hospital records and death data alone.  
 
 
Data protection and de-identification 
The processing and use of participant data are heavily regulated activities, 
particularly following the introduction of the General Data Protection Regulation 
(GDPR) in May 2018. This resulted in a specific communication to participants [30] 
setting out how the data that they had provided to UK Biobank were being used in 
accordance with the GDPR. Participant data provided to researchers are de-
identified, so that potentially identifying information is either not released (e.g., name, 
NHS number) or is modified (i.e. home location grid co-ordinates are rounded to 
1km; date of birth is restricted to month and year; certain brain images have facial 
features removed). UK Biobank is the only party that holds the necessary de-
encryption keys to undertake re-identification, and different identifiers are used 
across different UK Biobank internal databases to protect against inappropriate re-
identification (e.g., identifiable information is stored separately from phenotypic and 
genetic information; data collected during the imaging assessment have different 
identifiers to those of other data). Access to the keys that link the databases are 
highly restricted to designated staff to ensure the security of any identifiable data. 
Additionally, researchers agree when they sign the MTA prior to obtaining the data 
not to attempt to undertake re-identification of any participants for any purpose. 
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UK Biobank has a withdrawal process which allows a participant to withdraw from 
the resource at any time for any, or indeed no, reason.  To date, since recruitment 
started, fewer than 800 participants have asked to be removed from future data 
collection (including linkage to electronic health records) and fewer than 200 have 
asked for their data and samples to no longer be available for research purposes.  
 
Future direction: Dissemination of data 
The growing volume of data associated with the increasing richness of the UK 
Biobank resource will inevitably drive changes in the way those data are 
disseminated. Hitherto, the approach to data distribution has involved researchers 
downloading data to their own local computing environment. This has already proved 
challenging in certain cases. For example, to ensure access for all researchers at 
exactly the same time, the genotyping data were initially made available in encrypted 
form and then de-encrypted simultaneously only when all researchers had had the 
opportunity to download them (so as not to disadvantage researchers with slower 
download capabilities).  
The sheer volume of data associated with whole exome and whole genome 
sequencing of the entire cohort (currently estimated to be ~1PB and ~15PB, 
respectively) render unsustainable any approach based on distribution of data to 
researchers. UK Biobank is already starting to explore platform-based approaches, 
bringing researchers to the data rather than sending the data to researchers. By 
providing access to platforms which allow researchers to use the tools provided by 
the platform itself, or to run their own tools on the platform, the need to transfer data 
in bulk is avoided. Such a platform approach may also facilitate use of the UK 
Biobank resource by researchers at institutions that do not have a significant 
investment in local IT facilities, thus democratising further access to the data.  
 
Conclusion 
UK Biobank is being used by thousands of researchers worldwide for health-related 
research that is in the public interest. Its open-access strategy has enabled 
international scientists to produce excellent science and has led to external 
investment in enhancing the resource. As global interest in the resource grows, the 
data access process continues to be streamlined to enable researchers to obtain 
data quickly and easily. Open access of data to all researchers worldwide has 
encouraged both public and private investment, thereby enhancing this unique 
resource further. 
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Figure legends 
Fig. 1: Timeline of data collection and availability for UK Biobank participants 
by mid-2019. Pie chart indicates the proportion of the cohort that each data 
item is available for. 
a 
Data on exome sequencing data (for 50,000 participants) and serological markers of infectious 
agents (for 10,000 participants) were made available in March 2019, with the intention to 
assay all 500,000 participants over the next few years. 
 
Fig. 2:  Access metrics. (a) Number of international and UK researchers by 
year (b) Number of applications by year and country (c) Proportion of different 
types of submitted applications (d) Proportion of applications different types 
of data 
 
Fig. 3:  Research metrics. (a) Collaborations between the top 12 institutes (b) 
Number of publications by year (c) Areas of research output. 
a
Graph generated by Digital Science & Research Solutions Ltd 
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Table 1.  Observed and expected numbers of selected health outcomes in UK 
Biobank over timea 
 
Condition Incident cases 
observed by 
2016a 
Incident cases 
predicted by 
2026b 
Dementia   4,300 43,400 
Stroke   7,100 28,400 
Myocardial Infarction   8,000 22,000 
Chronic Obstructive Pulmonary Disease 17,600 55,000 
Parkinson’s Disease   2,000   9,700 
Breast cancer   7,000 18,000 
Prostate cancer   6,700 26,800 
Colorectal cancer   4,000 16,000 
 
a 
Based on linkage to hospital in-patient records, death certificates, cancer registries and primary care 
(the latter extrapolated to the full cohort) up until 01 Jan 2016. 
b
  Predicted numbers of cases were 
derived by applying ratios from a previous modelling exercise conducted for UK Biobank [31], which 
was based on UK age-specific disease incidence rates, adjusted to take account of the numbers of 
disease cases observed so far in UK Biobank participants (who have lower rates of most diseases 
compared with similar aged people in the general UK population) in linked healthcare data from 
primary and secondary care sources. 
A
cc
ep
te
d 
A
rt
ic
le
 
Exomesa
Baseline 
assessment
Active follow up
(data collection)
2006 - 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019  
Repeat 
assessment
Imaging 
assessment
24hr diet recall
Cognitive 
function
Occupational 
history
Mental 
health
Digestive  
health
Accelerometer
Accelerometer
Seasonal repeat
Questionnaires
(data collection)
Cancer registry
Death registry
Hospital admission data
Primary care 
data
Blood 
biomarkers
Interim 
genotype
Urine 
biomarkers
Genotype & 
imputation
Ongoing data collection
Passive follow up
(first availability 
for research)
Sample assays 
(first availability)
Infectious
Agentsa
Pain
This article is protected by copyright. All rights reserved. 
A
cc
ep
te
d 
A
rt
ic
le
 
18% 17%
28%
45%
55%
69%
78%
2012 2013 2014 2015 2016 2017 2018
0
1000
2000
3000
4000
UK International
N
um
be
r o
f r
es
ea
rc
he
rs
 2012 2013 2014 2015 2016 2017 2018
0
200
400
600
UK Rest of Europe USA Other
N
um
be
r o
f 
ap
pl
ic
at
io
ns
 
Data Only
 95%
Data + 
Samples
 4%
Recontact
 1%
 
95%
73%
63%
30% 24%
9%
De
ath
 &
 Ca
nc
er
Ge
ne
tic
s
Ho
sp
ita
l A
dm
iss
ion
 Da
ta
Im
ag
e D
eri
ve
d V
ari
ab
les
MR
I sc
an
s
Ra
w 
Ac
ce
ler
om
ete
r  
0%
20%
40%
60%
80%
100%
Pe
rc
en
ta
ge
 o
f a
pp
lic
at
io
ns
2a. Number of UK and international registered 
researchers by year
2b. Number of submitted applications by 
country and year 
2c. Proportion of different types of submitted 
applications 
2d. Proportion of applications requesting 
different types of data 
This article is protected by copyright. All rights reserved. 
A
cc
ep
te
d 
A
rt
ic
le
2013 2014 2015 2016 2017 2018
0
50
100
150
200
250
300
N
um
be
r o
f p
ub
lic
at
io
ns
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institutions using UK Biobank dataa 
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